Literature DB >> 10980819

Current experience with left ventricular assist devices in patients with congestive heart failure.

D Mancini1, M Oz, A Beniaminovitz.   

Abstract

Left ventricular assist devices are being used increasingly more often in patients with medically refractory heart failure. The HeartMate (Thermo Cardosystems Inc., Waltham, MA) and Novacor (Baxter Healthcare Corp., Deerfield, IL) assist devices are fully implantable devices that permit patients to be completely ambulatory. Presently, their chief application is as a bridge to cardiac transplantation, but the possibility that these devices could be used as long-term therapy in nontransplant patients is being investigated. The physiology of these devices, the complications of their long-term use, and the possibility of myocardial recovery after prolonged profound ventricular unloading are reviewed in this article. Finally, the exercise performance of patients using these devices is compared with that of patients with severe heart failure.

Entities:  

Mesh:

Year:  1999        PMID: 10980819     DOI: 10.1007/s11886-999-0040-x

Source DB:  PubMed          Journal:  Curr Cardiol Rep        ISSN: 1523-3782            Impact factor:   2.931


  20 in total

1.  Assessment of submaximal exercise capacity in patients with left ventricular assist devices.

Authors:  A Foray; D Williams; K Reemtsma; M Oz; D Mancini
Journal:  Circulation       Date:  1996-11-01       Impact factor: 29.690

2.  Regression of cellular hypertrophy after left ventricular assist device support.

Authors:  A Zafeiridis; V Jeevanandam; S R Houser; K B Margulies
Journal:  Circulation       Date:  1998-08-18       Impact factor: 29.690

Review 3.  Mechanical circulatory support and cardiac transplantation.

Authors:  S A Hunt; O H Frazier
Journal:  Circulation       Date:  1998-05-26       Impact factor: 29.690

4.  One hundred patients with the HeartMate left ventricular assist device: evolving concepts and technology.

Authors:  P M McCarthy; N O Smedira; R L Vargo; M Goormastic; R E Hobbs; R C Starling; J B Young
Journal:  J Thorac Cardiovasc Surg       Date:  1998-04       Impact factor: 5.209

5.  Delayed reversal of impaired metabolic vasodilation in patients with end-stage heart failure during long-term circulatory support with a left ventricular assist device.

Authors:  T Khan; H R Levin; M C Oz; S D Katz
Journal:  J Heart Lung Transplant       Date:  1997-04       Impact factor: 10.247

6.  Circulatory resuscitation with left ventricular assist device support reduces interleukins 6 and 8 levels.

Authors:  D J Goldstein; N Moazami; J A Seldomridge; H Laio; R C Ashton; Y Naka; D J Pinsky; M C Oz
Journal:  Ann Thorac Surg       Date:  1997-04       Impact factor: 4.330

7.  Exercise capacity recovers slowly but fully in patients with a left ventricular assist device.

Authors:  M Nishimura; B Radovancevic; P Odegaard; T Myers; W Springer; O H Frazier
Journal:  ASAIO J       Date:  1996 Sep-Oct       Impact factor: 2.872

8.  The effect of prolonged left ventricular support on myocardial histopathology in patients with end-stage cardiomyopathy.

Authors:  S A Scheinin; P Capek; B Radovancevic; J M Duncan; H A McAllister; O H Frazier
Journal:  ASAIO J       Date:  1992 Jul-Sep       Impact factor: 2.872

9.  Comparison of exercise performance in patients with chronic severe heart failure versus left ventricular assist devices.

Authors:  D Mancini; R Goldsmith; H Levin; A Beniaminovitz; E Rose; K Catanese; M Flannery; M Oz
Journal:  Circulation       Date:  1998-09-22       Impact factor: 29.690

10.  Early progressive mobilization of patients with left ventricular assist devices is safe and optimizes recovery before heart transplantation.

Authors:  T M Morrone; L A Buck; K A Catanese; R L Goldsmith; L P Cahalin; M C Oz; H R Levin
Journal:  J Heart Lung Transplant       Date:  1996-04       Impact factor: 10.247

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.